UsAgainstAlzheimer’s Applauds FDA Approval of Leqembi for Treatment of Early-Stage Alzheimer’s
06 juil. 2023 17h35 HE
|
UsAgainstAlzheimer's
Washington, DC, July 06, 2023 (GLOBE NEWSWIRE) -- Patient advocacy organization UsAgainstAlzheimer’s today hailed the first-of-its-kind traditional approval by the Food and Drug Administration (FDA)...
Collaborative AAPA, PA Foundation, Cleveland Clinic Alzheimer’s Early Detection Project Moves into Pilot Phase
28 juin 2023 10h59 HE
|
American Academy of PAs
Alexandria, VA, June 28, 2023 (GLOBE NEWSWIRE) -- Last year, the American Academy of PAs (AAPA), the PA Foundation, and Cleveland Clinic were awarded a grant from the Davos Alzheimer’s Collaborative...
DAVOS ALZHEIMER'S COLLABORATIVE HOSTS GLOBAL MEETING ON THE POWER OF HEALTH TECHNOLOGY FOR ALZHEIMER'S
31 mai 2023 18h13 HE
|
Davos Alzheimer's Collaborative
New York, NY, May 31, 2023 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC) will hold the fourth meeting of its Healthcare System Preparedness Learning Laboratory “The Power of...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
11 mai 2023 12h00 HE
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
Brain Health Academy Enrollment is Now Open, First Session Launches May 17
24 avr. 2023 11h05 HE
|
UsAgainstAlzheimer's
Washington, DC, April 24, 2023 (GLOBE NEWSWIRE) -- Following the launch of its highly successful Brain Health Academy in 2022, UsAgainstAlzheimer’s today announced class will be back in session...
Silo Pharma to Present at Psychedelic Drug Development Conference
24 avr. 2023 08h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
20 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...
Global Brain Monitoring Market to 2028: Increase in Incidence/Prevalence of Neurological Disorders Drives Growth
14 avr. 2023 09h43 HE
|
Research and Markets
Dublin, April 14, 2023 (GLOBE NEWSWIRE) -- The "Brain Monitoring Market, By Product Type, By Application, By End User, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028"...
New Study: Lowering Dementia Risk Takes Less BrainHQ Training than Expected
11 avr. 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Researchers report a relatively small amount of brain training is required to reduce dementia risk in the Body, Brain, Life for Cognitive...
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
20 mars 2023 08h45 HE
|
IGC Pharma, Inc.
POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC...